Contact us

Thank you for your interest in Garg Law PLLC.

Our commitment to understanding your regulatory questions and business goals, and helping you achieve results starts here.

If you are looking for representation on a new matter, please fill out the form below to request a free consultation. The form enables us to conduct a preliminary check for potential conflicts of interest and to determine if we can proceed with the free consultation.

FDA Issues Warning About Certain Supplements Substituted with Toxic Yellow Oleander

FDA Issues Warning About Certain Supplements Substituted with Toxic Yellow Oleander

What’s New

September 27, 2024

The FDA has added three additional products containing toxic yellow oleander to this Safety Alert. The complete list of products can be found in the chart below.

April 4, 2024

The FDA has completed analytical testing of an additional product which has similarly tested positive for yellow oleander. The FDA has received adverse event reports, including one report of a serious adverse event, for Green ELV Nutrition brand Elv Control Herbal Supplement (capsules). The product has been added to the table below.

March 12, 2024

The FDA continues to receive adverse event reports related to the products identified in this Safety Alert. The agency is reminding consumers to avoid these products because they contain toxic yellow oleander and can cause neurologic, gastrointestinal and cardiovascular adverse health effects that may be severe, or even fatal. The agency continues to communicate with firms selling these products. While a few have initiated voluntary recalls (please see the updates made to the table below), the FDA is concerned that products containing toxic yellow oleander remain on the marketplace. The FDA continues to evaluate additional regulatory pathways to remove all identified products from the marketplace.

The complete list of products can be found in the chart below.

Audience

  • All consumers

What is the problem?

  • FDA analysis has determined that certain dietary supplements labeled as tejocote (Crataegus mexicana) root or Brazil seed are adulterated because they were tested and found to be substituted with yellow oleander (Thevetia peruviana), a poisonous plant native to Mexico and Central America and a toxic substance of concern to public health officials. In other words, the tested products that were labeled as tejocote or Brazil seed are actually toxic yellow oleander.

Recommendations for consumers

  • The FDA is advising consumers to stop using and dispose of these products.
  • The FDA advises consumers who have taken any of these products of concern to contact their health care provider immediately.  Even if these products have not been used recently, consumers should still inform their health care provider about which product they took, so that an appropriate evaluation may be conducted.
  • Call 9-1-1 or get emergency medical help right away if you or someone in your care has serious side effects from these products.
  • Contact your healthcare provider if you or someone in your care recently ingested these products and have health concerns.
  • Consumers can also contact the state poison control center.

Summary and Scope of the Problem

In September 2023, the Centers for Disease Control and Prevention published a report of several tejocote root products found to be substituted with toxic yellow oleander. Based on this report, the FDA initiated an investigation to sample and test additional tejocote root products. As of 1/26/2024, the FDA tested as many as 18 samples, representing the products listed above, and found them to contain yellow oleander.

Based on the FDA’s sampling and testing results thus far, the FDA is also concerned that other products marketed as tejocote root (including with other names such as Crataegus mexicana, Raiz de Tejocote, and Mexican Hawthorn) may contain yellow oleander. Consuming yellow oleander can cause severe adverse health effects and be potentially fatal.

Actions

The FDA is actively working with the third-party platforms where these products are sold.

The FDA’s investigation is ongoing, and the FDA will continue to provide information on any further actions as it becomes available. Products may be added to this advisory. The FDA is working to further address the concerns related to these products and monitoring the market for adverse events, product complaints, and other emerging issues.

Request a Consultation

★★★★★

Working with Shelly on various new product launches over the last couple of years has been seamless. Quick and clear guidance is always what we get.
R.G. Client
I've been working with Shelly and her team at Garg law for a little while now and they are fantastic! Very responsive, professional and they certainly get things done. Extremely satisfied with their service and highly recommend.
Mike H. Client
Ms Garg helped my company navigate an FDA import issue. She achieved an excellent result, was very responsive and professional, and managed to keep the project within budget. She is a stellar attorney.
Dr. Sastry Client
I have been using Shelly Garg as FDA Counsel for 10+ years, since she was at another international law firm. While we continued to use the previous firm she was at (mainly due to the process required to change firms), we realized the quality of counsel was not the same. We have since been using Garg Law and the ease of use and trust in the knowledge was back instantly. Shelly has the skills to help me understand the regulations (by translating into layman's terms) and risks in a manner that is specific to my business. She is also extremely timely in her responses which is critical when we have a deadline mandated by the FDA. Many other attorneys cite the regulations which l've already read, but need further counsel. In my opinion, this demonstrates Shelly's in-depth knowledge of the regulations, how they pertain to the law, and how they are applicable IRL. Shelly's personable approach and pleasant manner in communication makes it very easy to have been work with her and have productive discussions on the best next steps. She truly has a passion iternational for all things FDA and I've learned so much from her.
Claire P. Client

News & Insights

Get the latest news on FDA regulatory delivered straight to your inbox.